2.08Open2.08Pre Close0 Volume3 Open Interest2.50Strike Price0.00Turnover0.00%IV-39.53%PremiumOct 18, 2024Expiry Date2.20Intrinsic Value100Multiplier16DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.23Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Beyond Air Stock Discussion
Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules
– Financing strengthens balance sheet and is expected to provide sufficient cash runway through June 2026 –
– Retiring $17.5 million in Avenue Capital debt, aided by $11.5 million in new debt from insider-led group; eliminates $12 million in scheduled debt payments through June 2026 –
– Avenue Capital, current insiders, and select group of healthcare-focuse...
Beyond Air Provides LungFit® PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed
Beyond Air, Inc. (NASDAQ: XAIR) has deployed its LungFit® PH system to the U.S. Naval Hospital Guam for neonatal critical care, in partnership with TrillaMed. The LungFit® PH system generates Nitric Oxide (NO) from room air to treat persistent pulmonary hypertension in neonates (PPHN). Key features include a portable design, advanced NO generating ...
Beyond Air® Publishes Peer-Reviewed Journal Article in Scientific Reports with Clinical Data Showing Nitric Oxide was Safe and Beneficial Adjunct Therapy for Subjects with Viral Pneumonia
Beyond Air (NASDAQ: XAIR) has published a peer-reviewed article in Scientific Reports, demonstrating the safety and benefits of nitric oxide (NO) as an adjunct therapy for viral pneumonia. The study, conducted on COVID-19 patients, showed that 150-ppm intermittent inhaled NO administer...
No comment yet